Your browser doesn't support javascript.
Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.
Albrecht, J Mark; Cooper, Benjamin R; Waller, Jacquelyn D; Presley, Colby L; Pulsipher, Kayd J; Rundle, Chandler W; Dellavalle, Robert P.
  • Dellavalle RP; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA Dermatology Service, U.S. Department of Veterans Affairs Rocky Mountain Regional Medical Center, Aurora, Colorado, USA. Robert.dellavalle@ucdenver.edu.
Dermatol Online J ; 29(1)2023 Feb 15.
Article in English | MEDLINE | ID: covidwho-2290922
ABSTRACT
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / COVID-19 Limits: Humans Language: English Journal subject: Dermatology Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / COVID-19 Limits: Humans Language: English Journal subject: Dermatology Year: 2023 Document Type: Article